A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. - Wikidata - awgldk - TriplyDB

A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease.

A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease.

http://www.wikidata.org/entity/Q37025979

about

Chemical probes of endocannabinoid metabolism Therapeutic potential of monoacylglycerol lipase inhibitors NO2 inhalation promotes Alzheimer's disease-like progression: cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome Activity-based proteomic and metabolomic approaches for understanding metabolism Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling.The Anti-Inflammatory Effects of Lipoxygenase and Cyclo-Oxygenase Inhibitors in Inflammation-Induced Human Fetal Glia Cells and the Aβ Degradation Capacity of Human Fetal Astrocytes in an Ex vivo Assay Endocannabinoid metabolism in neurodegenerative diseases Metabolomic strategies to map functions of metabolic pathways Endocannabinoids in synaptic plasticity and neuroprotection.Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids Exploring metabolic pathways and regulation through functional chemoproteomic and metabolomic platforms Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease.Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites.Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia.Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration.Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury.Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells Monoacylglycerol Lipase Regulates Fever Response Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity.Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α Deletion of Monoglyceride Lipase in Astrocytes Attenuates Lipopolysaccharide-induced Neuroinflammation Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease A chemical proteomic atlas of brain serine hydrolases identifies cell type-specific pathways regulating neuroinflammation.Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders Modulating the endocannabinoid system in human health and disease--successes and failures Synthesis and Preclinical Evaluation of Sulfonamido-based [(11)C-Carbonyl]-Carbamates and Ureas for Imaging Monoacylglycerol Lipase.Chemical approaches to study metabolic networks Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition.Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.Monoglyceride lipase: Structure and inhibitors.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.A novel live cell assay to measure diacylglycerol lipase α activity Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.

P2860

Q26863202-5B4CD989-D416-4B5E-B565-F6DA9DA3F1CE Q26991513-8E95AF1F-FC07-4194-A133-D67C5B624AC7 Q27334947-46AACE76-459C-4AFF-BC43-54926D2DAAB6 Q28300390-E69081E4-AE83-463D-A7AC-6482D186E4D4 Q28542515-156DB598-6ABA-42AE-BB3E-5FD9A0CDE184 Q30405653-6809A28F-F927-4327-A112-D76B0E623174 Q33620621-77C4D906-B92A-48E8-8909-522E9A894AE5 Q33736575-1AB37E12-5A59-445E-9D6A-78633B08DAD8 Q33811998-86D9A018-8CAC-40DE-A76A-AB88D24E00B0 Q34001321-B044C181-1E81-4D35-808E-75E47BEAF78A Q34084682-F348BE3D-329C-4226-BA7C-35AD9EA45D9B Q34156640-F052B710-B849-4E66-A7F1-B1535028C1EC Q34228026-0C5933DA-634F-42C8-8AAD-CCDBA62B1886 Q34451684-CA9A77A2-7ECF-44C0-AB12-282604469D0C Q34471868-CEAF3083-A4D2-48EB-92B6-5B8545213B19 Q34575719-967F0260-7010-462B-B676-B3B72F37B491 Q34933261-1663B396-28CC-4455-A9F5-8655FCD9677C Q35143497-81931685-B9F2-4460-844C-D926944EEF0E Q35559526-CDE26AC7-79A3-420F-8A7B-B0A42A237B01 Q35750166-38439051-B66D-46B1-B631-519094A33622 Q35896661-44FDBB1E-3A0E-4A5E-B6A9-5C530258CB21 Q35920709-FCC0432C-AAFE-44AE-BD6F-F20EFBA839D5 Q35999420-9C771852-8980-4D9D-B373-F03289DF72F3 Q36442442-E350A967-A9F3-48BC-81E0-6D89D620534D Q36442881-7B9C339E-36D4-4A82-B19D-8FBE37B8A847 Q36533991-88C53915-C9BC-460F-AA56-D324CCA13DF5 Q36594940-30B37205-F24A-4C9C-82B4-123B13EBC33D Q36933683-63E6ED43-1013-4055-9C56-BCFA147A82CD Q36970368-FAD5D3B0-6721-4A2F-AD70-537575712FDB Q37019550-EB91D32C-976C-4168-88BF-F8119DE6C12D Q37186197-1A915284-C443-485F-BE16-07EF66444BD7 Q37251595-13DFBFCF-3232-4D73-8C95-90B9AB091175 Q37338408-EB3A2A94-DD21-47C2-824B-4648116172B0 Q37577451-B9DC8FF4-E9EC-42B2-95D0-F205D7F9044E Q38196398-093AFC83-E173-4EA3-8063-094D2263EFBE Q38220272-08AE63C0-FF58-40FB-AE2A-88E851B6ED8B Q38555486-3C22F805-117C-4FE6-A397-6900F09468A8 Q38563981-BE6EEA16-4E49-4ED6-8D0D-3B35D915DC7C Q38783231-BB7DC15C-F424-47BC-980B-5F917D1EEF32 Q39042377-55DB27FB-F94C-44D7-972B-D5ADF26E61F5

P2860

A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease.

http://www.wikidata.org/entity/Q37025979

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 June 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A dysregulated endocannabinoid ...... model of Alzheimer's disease.

@en

A dysregulated endocannabinoid ...... model of Alzheimer's disease.

@nl

type

label

A dysregulated endocannabinoid ...... model of Alzheimer's disease.

@en

A dysregulated endocannabinoid ...... model of Alzheimer's disease.

@nl

prefLabel

A dysregulated endocannabinoid ...... model of Alzheimer's disease.

@en

A dysregulated endocannabinoid ...... model of Alzheimer's disease.

@nl

P1433

Q37025979-0D86B215-80F9-4971-AB83-763F13400D9C

P1476

Q37025979-A49FFAF9-E846-42F1-92F5-55D5930703A2

P2093

Q37025979-314002DF-C98A-423F-BA7B-09A0CD220E68

Q37025979-89AB5906-3BF9-419C-BD1D-77A62A1E803F

Q37025979-8B811278-110E-4826-849B-A8588E6537D1

Q37025979-BDF5D028-8FE3-42E0-8765-29D230E25242

Q37025979-C7E606F5-C35B-4CB5-AE6D-0B08B7472A5A

Q37025979-CFE635C8-773B-4EA2-BAAD-31B8D9B2E68A

Q37025979-D424A93C-3572-4DD5-A00D-378B0E4DE7AA

Q37025979-F41CD00F-6C61-41A2-97C3-8080C1020289

P2860

Q37025979-056E2AAD-2D20-4256-9EEB-A4DC25F61840

Q37025979-222379DC-F0D2-4167-AB77-E3C59AEA72FA

Q37025979-239F570C-E764-4602-99FB-1E6D00EAD74A

Q37025979-2C30A773-9632-4CA6-8446-84F945D63DE0

Q37025979-2E2A2D84-EEEB-482F-AF0F-9B50C35B6BC8

Q37025979-33BBEDFC-EA45-4E93-AF82-3A903D0C00A6

Q37025979-3631F150-CDEC-4B6F-AF2F-ED8B8EB3F220

Q37025979-445C8336-CB8C-420B-8456-639943BD5BCC

Q37025979-49F3E2EF-F06A-4F11-9309-08FD39044A8D

Q37025979-4C1FA1EB-FAC1-4244-A537-CEBC40518642

P304

Q37025979-D1B62D5D-53E7-47F9-9412-572DAF25C5EB

P31

Q37025979-E747CC39-B2B2-4040-AAEC-AD3D95E59A0F

P356

Q37025979-079133C9-AF03-4A34-B9DE-DFEC695C1F1B

P433

Q37025979-13C9E5F2-D3CC-4555-84A8-5A2AD333CD7B

P478

Q37025979-F1EB3CE4-3FEA-4AA1-B0E3-4618F8661238

P50

Q37025979-3514BD8E-E53D-424D-A252-4A315CFABB97

P577

Q37025979-7BBEA8DE-2B47-4124-870C-2B3E2FE66DFB

P5875

Q37025979-D39B8EC4-32B6-4E7B-B5ED-E015F092189A

P698

Q37025979-7B3C2D6D-FFB8-48A8-942C-63CB1D8ABBF2

P921

Q37025979-9468760C-838A-4A4D-B0AA-7E3792A81194

Q37025979-C7CDC4AE-48FD-4DE1-884F-04C2E644A116

Q37025979-D44AEFCA-86FD-40AC-B0E3-4E894B2748C0

P932

Q37025979-AAF0AD10-5C4B-48E8-9D92-DC81D0380497

P356

J.CELREP.2012.05.001

P1433

P1476

A dysregulated endocannabinoid ...... model of Alzheimer's disease.

@en

P2093

Cathleen Gonzales

http://www.w3.org/2001/XMLSchema#string

Daniel I Benjamin

http://www.w3.org/2001/XMLSchema#string

Daniel K Nomura

http://www.w3.org/2001/XMLSchema#string

James M Duerr

http://www.w3.org/2001/XMLSchema#string

Joel W Schwartz

http://www.w3.org/2001/XMLSchema#string

Kathleen M Wood

http://www.w3.org/2001/XMLSchema#string

Tarek A Samad

http://www.w3.org/2001/XMLSchema#string

YeQing Pi

http://www.w3.org/2001/XMLSchema#string

P2860

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?

The endocannabinoid system drives neural progenitor proliferation

Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease

Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system.

Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice

Mechanisms underlying inflammation in neurodegeneration

TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation.

Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.

Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid.

P304

617-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELREP.2012.05.001

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229425874

http://www.w3.org/2001/XMLSchema#string

P698

22813736

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

endocannabinoids

P932

3715876

http://www.w3.org/2001/XMLSchema#string